The Interim Report for the second quarter 2010 will be published around 8.30 a.m. (CET) July 20.
The Swedish Orphan Biovitrum AB (publ)´s Interim Report for the second quarter 2010 will be presented by Swedish Orphan Biovitrum´s CEO Martin Nicklasson and CFO Göran Arvidson at a media and analyst telephone conference the same day. The presentation will be held in English and can also be followed, direct or retrospectively, by an audio cast via internet.
Time: Tuesday, July 20, 2010 at 3 p.m. (CET) Telephone conference call: To participate in the Telephone Conference please call:
UK: +44 (0)207 509 5139 SWE: +46 (0)8 505 202 70 US: +1 718 354 1226
To follow the Telephone conference via audio cast, direct or retrospectively through internet you will find the link on our web site, please visit: www.sobi.com
The presentation material will be available on our web site 30 minutes prior to the telephone conference, please visit: www.sobi.com
Welcome!
Erik Kinnman, EVP, Head of Investor Relations & Public Affairs Phone: +46 8 697 21 50, erik.kinnman@sobi.com
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical company with an international market presence. The company is focused on providing and developing specialist pharmaceuticals for rare disease patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line. Our focus areas are: hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer supportive care and inherited metabolic disorders. Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visit www.sobi.com.
